Related Experiment Video
Updated: May 21, 2026
Contact Hypersensitivity as a Murine Model of Allergic Contact Dermatitis
Published on: September 26, 2022
A preliminary study on NLRP3 activation and the interventional effects of MCC950 in Con A-induced EAH mice
Di Ma1, Xinglou Liu1, Guo Ai1
1Department of Pediatrics, Tongji Hospital, Tongji Medical College and State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Disease, Huazhong University of Science and Technology, Wuhan, China.
Background:
MCC950 is a selective inhibitor of the NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome; however, its effects have not been explored in concanavalin A (Con A)-induced experimental autoimmune hepatitis (EAH) in mice. This study aims to investigate the involvement of the NLRP3 inflammasome pathway in the pathogenesis of Con A-induced EAH and to assess the therapeutic potential and mechanistic actions of MCC950 in this model.
Methods:
An EAH mouse model was established via Con A injection to investigate its pathogenesis. Mice were divided into four groups: control, MCC950, Con A, and Con A + MCC950. Liver and blood samples were collected at 0, 6, 12, and 24 hours post-injection. Multiple techniques were employed, including hematoxylin and eosin (HE) staining, enzyme-linked immunosorbent assay (ELISA), western blot, quantitative real-time polymerase chain reaction (qPCR), immunohistochemistry (IHC), and a FAM-FLICA caspase-1 activity assay. These approaches were used to evaluate liver histopathology, serum transaminase levels, expression of NLRP3 inflammasome pathway components, and the extent of pyroptosis.
Results:
In the Con A-induced EAH mouse model, significant increases in serum transaminase levels, the extent of liver histopathological damage, the expression of NLRP3, caspase-1, interleukin (IL)-1β, and IL-18, as well as pyroptosis activity levels, were observed at 12 hours post-injection compared to baseline (0 hours) (P<0.05). Following MCC950 treatment, all these parameters were markedly reduced relative to the Con A-only group (P<0.05), indicating a protective effect of NLRP3 inhibition in this model.
Conclusions:
MCC950 exerts a hepatoprotective effect in the Con A-induced EAH mouse model by suppressing the NLRP3 inflammasome pathway and reducing pyroptosis.
Insights
MCC950, an inhibitor of the NLRP3 inflammasome, demonstrates a protective effect against concanavalin A-induced experimental autoimmune hepatitis (EAH) in mice. Treatment with MCC950 significantly reduced liver damage and key inflammatory markers, indicating its therapeutic potential.
Area of Science:
- Immunology
- Hepatology
- Pharmacology
Background:
- Experimental autoimmune hepatitis (EAH) is an immune-mediated liver disease.
- The NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome is implicated in inflammatory conditions.
- The role of NLRP3 inflammasome in concanavalin A (Con A)-induced EAH and the therapeutic potential of MCC950 remain unexplored.
Purpose of the Study:
- To investigate the involvement of the NLRP3 inflammasome pathway in the pathogenesis of Con A-induced EAH.
- To evaluate the therapeutic efficacy of MCC950, a selective NLRP3 inhibitor, in a mouse model of EAH.
- To elucidate the mechanistic actions of MCC950 in mitigating EAH.
Main Methods:
- Establishment of a Con A-induced EAH mouse model.
- Administration of MCC950 to assess its protective effects.
- Collection and analysis of liver and blood samples at multiple time points.
- Histopathological examination (HE staining), biochemical assays (ELISA), molecular analyses (Western blot, qPCR), and pyroptosis assessment (caspase-1 activity assay).
Main Results:
- Con A injection led to significant increases in serum transaminases, liver damage, and expression of NLRP3 inflammasome components (NLRP3, caspase-1, IL-1β, IL-18) and pyroptosis.
- MCC950 treatment markedly reduced these pathological and molecular parameters compared to the Con A-only group.
- These findings indicate a protective role for MCC950 in the Con A-induced EAH model.
Conclusions:
- The NLRP3 inflammasome pathway plays a crucial role in the pathogenesis of Con A-induced EAH.
- MCC950 effectively suppresses the NLRP3 inflammasome pathway and pyroptosis in this model.
- MCC950 demonstrates significant hepatoprotective effects, highlighting its potential as a therapeutic agent for EAH.
More Related Videos
07:13Modified Experimental Conditions for Noise-Induced Hearing Loss in Mice and Assessment of Hearing Function and Outer Hair Cell Damage
Published on: February 10, 2023
06:29Inducing Ischemia-reperfusion Injury in the Mouse Ear Skin for Intravital Multiphoton Imaging of Immune Responses
Published on: December 22, 2016